Win For AZ's COPD Triple Combo In Bid To Catch GSK
Executive Summary
GlaxoSmithKline is streets ahead in the three-in-one COPD market, having received approval last year in the USA and Europe for Trelegy Ellipta, but AstraZeneca's PT010 may provide competition in the future having met six out of seven lung function primary endpoints in a Phase III trial.
You may also be interested in...
AstraZeneca’s COPD Triple Combo Drug Succeeds in ETHOS Phase III, Setting Up GSK Showdown
The triple-combination treatment significantly reduced COPD exacerbations compared to older dual therapies in the Phase III ETHOS study, providing a boost to AstraZeneca as it closes in on approvals in the US and Europe.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.